ReviewStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2014
Radioprotection of normal tissue cells.
Review in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Lenvatinib induces ferroptosis-related changes in osteosarcoma cells involving the p-STAT3/p53/xCT axis.Frontiers in oncology · 2026Article
- Radioprotectors & mitigators in radiation therapy: Harnessing diverse pathways for optimizing clinical outcomes.The Indian journal of medical research · 2025Review
- Topical EOSSKY fullerene moisturizing and repairing cream for preventing acute radiation dermatitis in breast cancer patients undergoing radiotherapy: a randomized controlled trial.Frontiers in medicine · 2025Article
- Comparative Analysis of Cystamine and Cysteamine as Radioprotectors and Antioxidants: Insights from Monte Carlo Chemical Modeling under High Linear Energy Transfer Radiation and High Dose Rates.International journal of molecular sciences · 2024Article
- Fluacrypyrim Protects Hematopoietic Stem and Progenitor Cells against Irradiation via Apoptosis Prevention.Molecules (Basel, Switzerland) · 2024Article
- Effect of adenosine treatment on ionizing radiation toxicity in zebrafish early life stages.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Radiotherapy in bone sarcoma: the quest for better treatment option.BMC cancer · 2023Review
- Exploring Natural Products as Radioprotective Agents for Cancer Therapy: Mechanisms, Challenges, and Opportunities.Cancers · 2023Review
- Nanodrugs with intrinsic radioprotective exertion: Turning the double-edged sword into a single-edged knife.Exploration (Beijing, China) · 2023Review
- Effect of low-level light therapy before radiotherapy in oral squamous cell carcinoma: An in vitro study.Lasers in medical science · 2022Article
- Article
- Progressive breast fibrosis caused by extreme radiosensitivity: Oncocytogenetic diagnosis and treatment by reconstructive flap surgery.Cancer reports (Hoboken, N.J.) · 2019Article
- Expanding the therapeutic index of radiation therapy by normal tissue protection.The British journal of radiology · 2019Review
- Dark tea extract mitigates hematopoietic radiation injury with antioxidative activity.Journal of radiation research · 2018Article
- The Addition of Manganese Porphyrins during Radiation Inhibits Prostate Cancer Growth and Simultaneously Protects Normal Prostate Tissue from Radiation Damage.Antioxidants (Basel, Switzerland) · 2018Article
- Radioprotective agents to prevent cellular damage due to ionizing radiation.Journal of translational medicine · 2017Review
- Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.Radiation research · 2017Article
- Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner.Oncogenesis · 2017Article
- Hydrogen-Rich Water Ameliorates Total Body Irradiation-Induced Hematopoietic Stem Cell Injury by Reducing Hydroxyl Radical.Oxidative medicine and cellular longevity · 2017Article
- The Yiqi and Yangyin Formula ameliorates injury to the hematopoietic system induced by total body irradiation.Journal of radiation research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvements of radiotherapy in combination with surgery and systemic therapy have resulted in increased survival rates of tumor patients. However, radiation-induced normal tissue toxicity is still dose limiting. Several strategies have been pursued with the goal to develop substances which may prevent or reduce damage to normal tissue. Drugs applied before radiotherapy are called radioprotectors; those given after radiotherapy to reduce long-term effects are radiomitigators. Despite more than 50 years of research, until now only two substances, amifostine and palifermin, have overcome all obstacles of clinical approval and are applied during radiotherapy of head and neck cancer or total body irradiation, respectively. However, better understanding of the cellular pathways involved in radiation response has allowed the development of several highly promising drugs functioning as scavengers of reactive oxygen species or targeting specific molecules involved in regulation of cell death pathways or cell cycle arrest. The present review describes the major targets for radioprotectors or radiomitigators currently tested in clinical trials.
Indexed as
Identifiers
24638269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.